- Preliminary data from ongoing Phase 1 clinical studies of micvotabart pelidotin (MICVO) in patients with recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) expected in the ...
BOSTON, Oct. 13, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, announced today that it will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results